Kongfei L. Li

Ningbo, China

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 17 publications

Anti-CD22 Calicheamicin-Inotuzumab Ozogamicin Combined with Venetoclax + Azacitidine in the Treatment of Mixed-Phenotype Acute Leukemia: A Case Report

Anti-CD22 Calicheamicin-Inotuzumab Ozogamicin Combined with Venetoclax + Azacitidine in the Treatment of Mixed-Phenotype Acute Leukemia: A Case Report

Journal: Turkish journal of haematology : official journal of Turkish Society of Haematology
Published: July 30, 2024

Moderate-To-Severe Bone Marrow Fibrosis Is an Independent Risk Factor For Myelodysplastic Neoplasms Patients With Increased Blasts.

Moderate-To-Severe Bone Marrow Fibrosis Is an Independent Risk Factor For Myelodysplastic Neoplasms Patients With Increased Blasts.

Journal: Hematological oncology
Published: July 25, 2024

Primary refractory diffuse large B-cell lymphoma of the uterine cervix metastasizing to the kidney: A case report.

Primary refractory diffuse large B-cell lymphoma of the uterine cervix metastasizing to the kidney: A case report.

Journal: Asian journal of surgery
Published: December 22, 2023

Blockade of de novo pyrimidine biosynthesis triggers autophagic degradation of oncoprotein FLT3-ITD in acute myeloid leukemia.

Blockade of de novo pyrimidine biosynthesis triggers autophagic degradation of oncoprotein FLT3-ITD in acute myeloid leukemia.

Journal: Oncogene
Published: May 23, 2023

A Novel Prognostic Scoring Model for Myelodysplastic Syndrome Patients With SF3B1 Mutation.

A Novel Prognostic Scoring Model for Myelodysplastic Syndrome Patients With SF3B1 Mutation.

Journal: Frontiers in oncology
Published: March 27, 2022

All-trans retinoic acid enhances the cytotoxic effect of decitabine on myelodysplastic syndromes and acute myeloid leukaemia by activating the RARα-Nrf2 complex.

All-trans retinoic acid enhances the cytotoxic effect of decitabine on myelodysplastic syndromes and acute myeloid leukaemia by activating the RARα-Nrf2 complex.

Journal: British journal of cancer
Published: February 26, 2022

High expression of COMMD7 is an adverse prognostic factor in acute myeloid leukemia.

High expression of COMMD7 is an adverse prognostic factor in acute myeloid leukemia.

Journal: Aging
Published: November 06, 2020

Epigenetic priming with decitabine followed by low dose idarubicin and cytarabine in acute myeloid leukemia evolving from myelodysplastic syndromes and higher-risk myelodysplastic syndromes: a prospective multicenter single-arm trial.

Epigenetic priming with decitabine followed by low dose idarubicin and cytarabine in acute myeloid leukemia evolving from myelodysplastic syndromes and higher-risk myelodysplastic syndromes: a prospective multicenter single-arm trial.

Journal: Hematological oncology
Published: March 02, 2020

E2F1 mediated DDX11 transcriptional activation promotes hepatocellular carcinoma progression through PI3K/AKT/mTOR pathway.

E2F1 mediated DDX11 transcriptional activation promotes hepatocellular carcinoma progression through PI3K/AKT/mTOR pathway.

Journal: Cell death & disease
Published: December 19, 2019

UBQLN4 promotes progression of HCC via activating wnt-β-catenin pathway and is regulated by miR-370.

UBQLN4 promotes progression of HCC via activating wnt-β-catenin pathway and is regulated by miR-370.

Journal: Cancer cell international
Published: August 28, 2019

Modified cladribine, cytarabine, and G-CSF as a salvage regimen in patients with relapsed/refractory acute myeloid leukemia: a bridge to myeloablative allogeneic hematopoietic stem cell transplantation.

Modified cladribine, cytarabine, and G-CSF as a salvage regimen in patients with relapsed/refractory acute myeloid leukemia: a bridge to myeloablative allogeneic hematopoietic stem cell transplantation.

Journal: Annals of hematology
Published: February 23, 2019

CBX2 is a functional target of miRNA let-7a and acts as a tumor promoter in osteosarcoma.

CBX2 is a functional target of miRNA let-7a and acts as a tumor promoter in osteosarcoma.

Journal: Cancer medicine
Published: November 10, 2018
Showing 1-12 of 17

Last Updated: 09/26/2026